製品番号: HY-139848

WS-898

カスタマーレビュー

Based on 1 Customer Validation

WS-898 is a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC₅₀ = 5.0, 3.67, and 3.68 nM, respectively).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.51%
CAS 番号: 2891562-77-7
分子式: C₃₃H₂₅N₇OS
分子量:567.66

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

WS-898 構造式

CAS 番号: 2891562-77-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	1.31 μM Compound: 26	Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/pcDNA3.1 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1.93 +/- 0.06 nM Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/pcDNA3.1 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1.93 +/- 0.06 nM	[PMID: 34723530]
HEK293	IC₅₀	1.69 μM Compound: 26	Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/pcDNA3.1 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1.93 +/- 0.06 nM Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/pcDNA3.1 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1.93 +/- 0.06 nM	[PMID: 34723530]
HEK293	IC₅₀	3.68 μM Compound: 26	Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/ABCB1 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 91.40 +/- 23.32 nM) Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/ABCB1 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 91.40 +/- 23.32 nM)	[PMID: 34723530]
HEK293	IC₅₀	9.21 μM Compound: 26	Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/ABCB1 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 91.40 +/- 23.32 nM) Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/ABCB1 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 91.40 +/- 23.32 nM)	[PMID: 34723530]
KB 3-1	IC₅₀	3.53 μM Compound: 26	Reversal of resistance to paclitaxel-induced cytotoxicity in human KB 3-1 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.54 +/- 1.59 nM) Reversal of resistance to paclitaxel-induced cytotoxicity in human KB 3-1 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.54 +/- 1.59 nM)	[PMID: 34723530]
KB 3-1	IC₅₀	4.09 μM Compound: 26	Reversal of resistance to paclitaxel-induced cytotoxicity in human KB 3-1 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.54 +/- 1.59 nM) Reversal of resistance to paclitaxel-induced cytotoxicity in human KB 3-1 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.54 +/- 1.59 nM)	[PMID: 34723530]
KB-C2	IC₅₀	15.94 μM Compound: 26	Reversal of resistance to paclitaxel-induced cytotoxicity in human KB-C2 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1886.37 +/- 243.05 nM) Reversal of resistance to paclitaxel-induced cytotoxicity in human KB-C2 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1886.37 +/- 243.05 nM)	[PMID: 34723530]
KB-C2	IC₅₀	3.67 μM Compound: 26	Reversal of resistance to paclitaxel-induced cytotoxicity in human KB-C2 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1886.37 +/- 243.05 nM) Reversal of resistance to paclitaxel-induced cytotoxicity in human KB-C2 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1886.37 +/- 243.05 nM)	[PMID: 34723530]
SW-620	IC₅₀	0.005 μM Compound: 26	Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620/AD300 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.23 +/- 0.50 uM) Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620/AD300 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.23 +/- 0.50 uM)	[PMID: 34723530]
SW-620	IC₅₀	28.15 nM Compound: 26	Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620/AD300 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.23 +/- 0.50 uM) Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620/AD300 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.23 +/- 0.50 uM)	[PMID: 34723530]
SW-620	IC₅₀	6.98 μM Compound: 26	Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 7.69 +/- 2.78 nM) Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 7.69 +/- 2.78 nM)	[PMID: 34723530]
SW-620	IC₅₀	7.19 μM Compound: 26	Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 7.69 +/- 2.78 nM) Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 7.69 +/- 2.78 nM)	[PMID: 34723530]

化学情報

CAS 番号 2891562-77-7
性状 Solid
分子量 567.66
分子式 C₃₃H₂₅N₇OS
Color Light yellow to yellow
SMILES

O=C(/C=C/C1=CC=C(C=CC=C2)C2=C1)C3=CC=C(NC4=CC(C)=NC5=NC(SCC6=NC7=C(C=CC=C7)N6)=NN54)C=C3
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : ≥ 25 mg/mL (44.04 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7616 mL

8.8081 mL

17.6162 mL

5 mM

0.3523 mL

1.7616 mL

3.5232 mL

10 mM

0.1762 mL

0.8808 mL

1.7616 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (276 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Wang S, et al. Discovery of the Triazolo[1,5-a]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance. J Med Chem. 2021 Nov 11;64(21):16187-16204. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7616 mL	8.8081 mL	17.6162 mL	44.0404 mL
	5 mM	0.3523 mL	1.7616 mL	3.5232 mL	8.8081 mL
	10 mM	0.1762 mL	0.8808 mL	1.7616 mL	4.4040 mL
	15 mM	0.1174 mL	0.5872 mL	1.1744 mL	2.9360 mL
	20 mM	0.0881 mL	0.4404 mL	0.8808 mL	2.2020 mL
	25 mM	0.0705 mL	0.3523 mL	0.7046 mL	1.7616 mL
	30 mM	0.0587 mL	0.2936 mL	0.5872 mL	1.4680 mL
	40 mM	0.0440 mL	0.2202 mL	0.4404 mL	1.1010 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

WS-898

Bioactive Compound Library Max

Bioactive Compound Library

Membrane Transporter/Ion Channel Compound Library

Anti-Cancer Compound Library

Cancer Stem Cells Compound Library

Anti-Drug-Resistant Compound Library

Anti-Ovarian Cancer Compound Library

MCE Bioactive Compound Library

High-Throughput Bioactive Compound Library

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

WS-898

Bioactive Compound Library Max

Bioactive Compound Library

Membrane Transporter/Ion Channel Compound Library

Anti-Cancer Compound Library

Cancer Stem Cells Compound Library

Anti-Drug-Resistant Compound Library

Anti-Ovarian Cancer Compound Library

MCE Bioactive Compound Library

High-Throughput Bioactive Compound Library

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

WS-898 関連分類

HY-139848 関連分類